Eurofins Scientific SE

LSE:0MV5 Stock Report

Market Cap: €8.9b

Eurofins Scientific Valuation

Is 0MV5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MV5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0MV5 (€47.04) is trading below our estimate of fair value (€142.93)

Significantly Below Fair Value: 0MV5 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MV5?

Key metric: As 0MV5 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0MV5. This is calculated by dividing 0MV5's market cap by their current earnings.
What is 0MV5's PE Ratio?
PE Ratio27.3x
Earnings€325.90m
Market Cap€8.89b

Price to Earnings Ratio vs Peers

How does 0MV5's PE Ratio compare to its peers?

The above table shows the PE ratio for 0MV5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.2x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
8.6x-15.2%UK£149.7m
HIK Hikma Pharmaceuticals
19x12.8%UK£4.3b
QGEN Qiagen
102.3x34.4%US$9.5b
0MV5 Eurofins Scientific
27.3x18.3%€8.9b

Price-To-Earnings vs Peers: 0MV5 is good value based on its Price-To-Earnings Ratio (27.3x) compared to the peer average (43.3x).

Price to Earnings Ratio vs Industry

How does 0MV5's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0MV5 27.3xIndustry Avg. 37.1xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0MV5 is good value based on its Price-To-Earnings Ratio (27.3x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is 0MV5's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MV5 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.3x
Fair PE Ratio28.7x

Price-To-Earnings vs Fair Ratio: 0MV5 is good value based on its Price-To-Earnings Ratio (27.3x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MV5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€47.04
€59.52
+26.5%
21.0%€89.00€42.00n/a16
Nov ’25€45.72
€59.52
+30.2%
21.0%€89.00€42.00n/a16
Oct ’25€57.08
€60.34
+5.7%
18.8%€90.00€44.00n/a16
Sep ’25€52.12
€59.91
+14.9%
18.6%€90.00€44.00n/a17
Aug ’25€54.76
€60.35
+10.2%
18.1%€90.00€44.00n/a17
Jul ’25€47.27
€59.69
+26.3%
17.1%€83.00€44.00n/a16
Jun ’25€55.48
€60.88
+9.7%
15.0%€83.00€48.00n/a16
May ’25€57.60
€60.88
+5.7%
15.0%€83.00€48.00n/a16
Apr ’25€59.09
€59.03
-0.1%
15.7%€84.00€48.00n/a16
Mar ’25€55.28
€58.66
+6.1%
14.5%€80.00€48.00n/a17
Feb ’25€54.49
€57.42
+5.4%
16.4%€80.00€45.00n/a17
Jan ’25€59.16
€57.65
-2.5%
16.4%€80.00€45.00n/a17
Dec ’24€53.51
€57.92
+8.2%
17.7%€81.00€45.00n/a17
Nov ’24€48.23
€61.98
+28.5%
24.6%€105.00€45.00€45.7217
Oct ’24€53.61
€65.79
+22.7%
20.2%€105.00€48.00€57.0817
Sep ’24€56.63
€66.88
+18.1%
21.5%€105.00€48.00€52.1215
Aug ’24€60.52
€66.61
+10.1%
20.8%€105.00€48.00€54.7615
Jul ’24€58.04
€66.80
+15.1%
19.6%€105.00€50.00€47.2716
Jun ’24€61.32
€65.98
+7.6%
20.1%€105.00€50.00€55.4817
May ’24€63.00
€67.22
+6.7%
21.5%€105.00€50.00€57.6017
Apr ’24€61.63
€68.92
+11.8%
20.9%€105.00€50.00€59.0915
Mar ’24€58.72
€73.85
+25.8%
19.5%€105.00€51.92€55.2814
Feb ’24€65.82
€78.53
+19.3%
23.4%€125.00€51.92€54.4915
Jan ’24€68.30
€81.85
+19.8%
21.3%€125.00€51.92€59.1614
Dec ’23€68.36
€82.07
+20.0%
21.3%€125.00€51.92€53.5114
Nov ’23€64.75
€84.62
+30.7%
21.1%€125.00€51.92€48.2316

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%